Midday Watch: Ambarella (AMBA), BioCryst (BCRX), Uranium Energy (UEC), Healthways (HWAY)

Shares of Ambarella (AMBA) are down 6.32% to $118.70 in midday trading Friday following cautious mention at Citron. The publication notes the video processing chip designer, which makes chips that process video for a number of companies including GoPro (GPRO), isn’t disrupting the industry or defining a new marketplace. According to Citron, AMBA is worth $30 a share, implying 75% expected downside.

BioCryst Pharmaceuticals, Inc. (BCRX) shares are up 4.25% to $15.10 in midday trading. The move comes on a big volume too with the issue currently trading more than 1.5 million shares, compared to the average volume of 903K shares. Not seeing any news or rumors to account for the move.

BioCryst Pharmaceuticals is a Durham, North Carolina-based biotechnology firm that focuses on the development of small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its stock has a median consensus analyst price target of $18 with a high target of $23.00, and a 52-week trading range of $7.85 to $15.21.

The T-12 profit margin at BioCryst Pharmaceuticals is (295%). BCRX revenue for the same period is $19.98 million.

Uranium Energy Corp. (UEC) is plunging 25 percent to $1.82 following its response to recent press releases relying on what the company calls “unfounded allegations of a third party”. Uranium Energy said the subject press releases have absolutely no merit and are comprised of unfounded allegations made by a third party whose motives are questionable.

Healthways Inc. (HWAY) is down 19.6 percent to $12.25 on heavy trading volume Friday as the health services company lowered its FY15 revenue forecast, citing multiple reasons.

Healthways cut its 2015 revenue guidance to a range of $770 – $785 million from its previous range of $800 – $825 million. Analysts surveyed by Thomson Reuters had forecast revenue of $804.48 million for the year. As a result of revised guidance, Dougherty & Company this morning reduced their price target on the name to $15 from $25.

Be the first to comment

Leave a Reply

Your email address will not be published.


*